

PERSONAL INFORMATIONS **Alessio Ardizzone**

<https://orcid.org/0000-0002-2293-0634>

CURRENT POSITION
27/10/2025-TO DATE

Researcher Tenure Track (RTT), GSD BIOS-11A, ex SSD BIO/14, at UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.

EDUCATIONAL AND ACADEMIC
BACKGROUND

2025 National Scientific Qualification for the position of associate professor in 05/G1 "Pharmacology, clinical pharmacology, and pharmacognosy" (GSD BIOS-11A, formerly SSD BIO/14), from March 7, 2025, to March 7, 2037.

2025-to date Second Level Master's Degree in Techniques for the Preparation of Antineoplastic Drugs and Assessment of the Safety and Efficacy of Medical Devices from the University of Messina.

01/07/2024-26/10/2025 RTD-A, Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Messina (Law 240/2010).

2024-to date Second-year specialist in Pharmacology and Clinical Toxicology (non-medical field)

2023-2024 Second Level Master's Degree in "Pharmacovigilance: safety monitoring, risk management, quality assurance in the digital health era" at the Department of Pharmacological and Biomolecular Sciences of the University of Milan, obtained on 04/29/2024. Thesis: DPYD*6 polymorphism screening is a useful tool for decreasing gastrointestinal and hematological adverse drug reactions risk in fluoropyrimidine-treated patients (Field: BIOS-11/A, previously SSD BIO/14); Tutor: Prof. Emanuela Esposito.

2023-to date Subject expert for the discipline "Pharmacology with Insights into Neuropharmacology and Molecular Toxicology" – Bachelor's Degree in Health Biology and Nutrition Technologies (Field: BIOS-11/A, previously SSD BIO/14), at the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina.

2023-2024 Research Fellow at the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences (ChiBioFarAm) of the University of Messina (from 17/04/2023 to 16/04/2024; 12 months). Project: "New therapeutic approaches in the modulation of inflammatory processes in central nervous system trauma and

neurodegenerative diseases" (Field: BIOS-11/A, previously SSD BIO/14); Tutor: Prof. Salvatore Cuzzocrea

- 2021-2022** Affiliated researcher at the Institute for Infection, Immunity, and Inflammation at the University of Glasgow, Glasgow, UK, in Prof. Pasquale Maffia's laboratory. Projects: "Defining the individual and integrated roles of inflammatory chemokine receptors (iCCRs) in atherosclerosis" and "Defining the roles of the IL-21/IL-21 receptor axis in atherosclerosis" (19/10/2021-31/10/2022). Supervisor: Prof. Pasquale Maffia
- 2019-2022** PhD in Applied Biology and Experimental Medicine (XXXV cycle) at the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences (ChiBioFarAm) of the University of Messina. Awarded on November 4, 2022, grade: Excellent with honors. Thesis title: "Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion" (Field: BIOS-11/A, previously SSD BIO/14). Supervisor: Prof. Emanuela Esposito
- 2020** License to practice as a pharmacist (January 10, 2020)
- 2019** Master's Degree in Pharmaceutical Chemistry and Technology on July 24, 2019, from the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences (ChiBioFarAm) at the University of Messina. Thesis title: "Neuroprotective effects of 2-pentadecyl-2-oxazoline (PEA-OXA) in a model of cerebral ischemia in diabetic rats" (Field: BIOS-11/A, previously SSD BIO/14). Supervisor: Prof. Salvatore Cuzzocrea
- 2018-2019** Internship aimed at completing an experimental thesis at the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences (ChiBioFarAm) of the University of Messina, in the Pharmacology Laboratory of Prof. Salvatore Cuzzocrea and Prof. Emanuela Esposito.

TEACHING ACTIVITIES

- 2024-26/10/2025** Supplementary teaching (1 credit), for the subject Clinical Biochemistry and Clinical Molecular Biology (BIOS-09A, previously BIO/12) taught by Prof. Daniela Impellizzeri in the degree course in Health Biology, Applied Technologies, and Nutrition, University of Messina.
- 2023-to date** Subject expert for the discipline "Pharmacology with Insights into Neuropharmacology and Molecular Toxicology" – bachelor's degree in health biology and nutrition technologies (BIOS-11/A, previously SSD BIO/14), at the Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina.

- 2019-2022** Teaching support for laboratory activities and lectures for the course "PHARMACOLOGY WITH IN-DEPTH STUDY OF NEUROPHARMACOLOGY AND MOLECULAR TOXICOLOGY" (BIOS-11/A, previously SSD BIO/14) (LM-6) taught by Prof. Esposito, Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina.
- 2022-26/10/2025** Teaching support for lectures in the course "FOOD TOXICOLOGY" (BIOS-11/A, previously SSD BIO/14) (LM-61) taught by Prof. Paterniti, Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina.
- 2022-26/10/2025** Teaching support for laboratory activities and lectures for the course "PHYSIOLOGY AND PHARMACOLOGY," Pharmacology Module (BIOS-11/A, previously SSD BIO/14), (L-13) taught by Prof. Campolo, Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina.
- 2021-26/10/2025** Teaching support for the activities of the Level II Master's Degree in "Techniques for the preparation of antineoplastic drugs and assessment of the safety and efficacy of medical devices" directed by Prof. Esposito, University of Messina.
- 2019-26/10/2025** Support for laboratory activities aimed at drafting experimental theses by students enrolled in Prof. Esposito's Pharmacology laboratory (BIOS-11/A, previously SSD BIO/14) at the Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina.

RESIDENCY AT RESEARCH INSTITUTES

- 2021-2022** Affiliated researcher at the Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, in the laboratory of Prof. Pasquale Maffia (19/10/2021-31/10/2022).
Projects: "Defining the individual and integrated roles of inflammatory chemokine receptors (iCCRs) in atherosclerosis" and "Defining the role of the IL-21/IL-21 receptor axis in atherosclerosis." Supervisor: Prof. Pasquale Maffia.

PARTICIPATION IN PROJECTS

- 2022-2024** Participation in the PRIN 2020 project. Project title: "New interventional approaches on multiple inflammatory pathways involved in regeneration after trauma and aging-associated diseases," at the Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina. (from January 1, 2022, to April 16, 2024).
Code: 202039WMFP_001
Scientific director: Salvatore Cuzzocrea
Scientific coordinator: Salvatore Cuzzocrea
Co-funding: MIUR
- 2022-26/10/2025** Participation in the PRIN 2022 project. Project title: "Insights into the prognostic

value and immunological role of NAEs degradative enzymes in brain tumors,” at the Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina (from January 1, 2024 – October 26, 2025).

Code: 20223XBJYT_001

Scientific director: Emanuela Esposito

Scientific coordinator: Emanuela Esposito

Co-funding: MIUR

2022 – 2023 Participation in the Liver Smart Drug (LSD) project, coordinated by the Micro and Nano Systems Technology District of Sicily and supported in its research activities by the Universities of Catania, Palermo, and Messina, carried out at the Department of Chemical, Pharmacological, and Environmental Sciences, University of Messina (from November 1, 2022, to May 31, 2023).

2024-26/10/2025 Participation in the AdvaNced Technology for Human centERed Medicine (ANTHEM) project funded by the Ministry of University and Research as part of the National Complementary Plan (PNC) for the identification of new therapeutic targets and molecular biomarkers in Parkinson's disease and glioblastoma. Activity carried out at the Department of Chemical, Pharmacological and Environmental Sciences, University of Messina (from January 1, 2024, to October 26, 2025).

COLLABORATIONS WITH RESEARCH INSTITUTES AND COMPANIES

2020 – 2024 Collaboration with the Mediterranean Oncology Institute (IOM) with the production of the following publications:

- **Ardizzone A**, Scuderi SA, Giuffrida D, Colarossi C, Puglisi C, Campolo M, Cuzzocrea S, Esposito E, Paterniti I. Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. *Cancers (Basel)*. 2020 Dec 18;12(12):3825. doi: 10.3390/cancers12123825. PMID: 33352931; PMCID: PMC7766440.

- **Ardizzone A**, Calabrese G, Campolo M, Filippone A, Giuffrida D, Esposito F, Colarossi C, Cuzzocrea S, Esposito E, Paterniti I. Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis. *Int J Mol Sci*. 2021 Apr 29;22(9):4697. doi: 10.3390/ijms22094697. PMID: 33946718; PMCID: PMC8125123.

- Scuderi SA, Casili G, **Ardizzone A**, Forte S, Colarossi L, Sava S, Paterniti I, Esposito E, Cuzzocrea S, Campolo M. KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces Glioblastoma Proliferation through Angiogenesis and Apoptosis Modulation. *Cancers (Basel)*. 2021 Jul 9;13(14):3444. doi: 10.3390/cancers13143444. PMID: 34298658; PMCID: PMC8306782.

- Repici A, **Ardizzone A**, Filippone A, Colarossi C, Mare M, Raciti G, Mannino D, Cuzzocrea S, Paterniti I, Esposito E. Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential. *Cells*. 2023 Sep 15;12(18):2284. doi: 10.3390/cells12182284. PMID: 37759505; PMCID: PMC10526836.

- **Ardizzone A**, Basilotta R, Filippone A, Crupi L, Lanza M, Lombardo SP, Colarossi C, Sciacca D, Cuzzocrea S, Esposito E, Campolo M. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. *Cells*. 2023 Mar 8;12(6):841. doi:

10.3390/cells12060841. PMID: 36980182; PMCID: PMC10046911.

- **Ardizzone A**, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, Colarossi C, Mare M, Cuzzocrea S, Esposito E, Paterniti I. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value. *Cells*. 2023 Mar 24;12(7):1002. doi: 10.3390/cells12071002. PMID: 37048074; PMCID: PMC10093572.

- Repici A, **Ardizzone A**, De Luca F, Colarossi L, Prestifilippo A, Pizzino G, Paterniti I, Esposito E, Capra AP. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma. *Cells*. 2024 Feb 19;13(4):361. doi: 10.3390/cells13040361. PMID: 38391974; PMCID: PMC10886920.

2020 Collaboration with the National Research Council (CNR) in Catania with the production of the following publications:

- Filippone A, Consoli GML, Granata G, Casili G, Lanza M, **Ardizzone A**, Cuzzocrea S, Esposito E, Paterniti I. Topical Delivery of Curcumin by Choline-Calix[4]arene-Based Nanohydrogel Improves Its Therapeutic Effect on a Psoriasis Mouse Model. *Int J Mol Sci*. 2020 Jul 17;21(14):5053. doi: 10.3390/ijms21145053. PMID: 32708987; PMCID: PMC7404063.

2020 – to date Collaboration with the pharmaceutical company Epitech Group on the production of the following publications:

- Casili G, Lanza M, Campolo M, Siracusa R, Paterniti I, **Ardizzone A**, Scuderi SA, Cuzzocrea S, Esposito E. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation. *Int J Mol Sci*. 2020 Oct 11;21(20):7486. doi: 10.3390/ijms21207486. PMID: 33050589; PMCID: PMC7589809.

- Campolo M, Lanza M, Paterniti I, Filippone A, **Ardizzone A**, Casili G, Scuderi SA, Puglisi C, Mare M, Memeo L, Cuzzocrea S, Esposito E. PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF- κ B/Nrf-2 Axis. *Int J Mol Sci*. 2021 Apr 10;22(8):3927. doi: 10.3390/ijms22083927. PMID: 33920318; PMCID: PMC8069952.

- Campolo M, Crupi R, Cordaro M, Cardali SM, **Ardizzone A**, Casili G, Scuderi SA, Siracusa R, Esposito E, Conti A, Cuzzocrea S. Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury. *Int J Mol Sci*. 2021 Aug 13;22(16):8717. doi: 10.3390/ijms22168717. PMID: 34445417; PMCID: PMC8395716.

- **Ardizzone A**, Fusco R, Casili G, Lanza M, Impellizzeri D, Esposito E, Cuzzocrea S. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-L-Carnitine on Experimental Model of Inflammatory Pain. *Int J Mol Sci*. 2021 Feb 17;22(4):1967. doi: 10.3390/ijms22041967. PMID: 33671213; PMCID: PMC7922157.

- Capra AP, **Ardizzone A**, Crupi L, Calapai F, Campolo M, Cuzzocrea S, Esposito E. Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies. *Biomedicines*. 2023 Aug 3;11(8):2189. doi: 10.3390/biomedicines11082189. PMID: 37626685; PMCID: PMC10452638.

- Crupi L, Capra AP, Paterniti I, Lanza M, Calapai F, Cuzzocrea S, **Ardizzone A***, Esposito E. Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. *Nat Prod Res*. 2024 Jan 25:1-20. doi: 10.1080/14786419.2024.2306916. Epub ahead of print. PMID: 38269580.
*corresponding author

2020 – to date Collaboration with the pharmaceutical company DEVINTEC in the production of the following publications:

- Campolo M, Lanza M, Filippone A, Paterniti I, Casili G, Scuderi SA, **Ardizzone A**, Cuzzocrea S, Esposito E. Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier

Permeability. *Skin Pharmacol Physiol*. 2020;33(4):231-236. doi: 10.1159/000509372. Epub 2020 Aug 26. PMID: 32846412.

- Campolo M, Casili G, Paterniti I, Filippone A, Lanza M, **Ardizzone A**, Scuderi SA, Cuzzocrea S, Esposito E. Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis. *Int J Mol Sci*. 2020 May 19;21(10):3596. doi: 10.3390/ijms21103596. PMID: 32438777; PMCID: PMC7279434.

- **Ardizzone A**, Lanza M, Casili G, Campolo M, Paterniti I, Cuzzocrea S, Esposito E. Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion. *Nutrients*. 2022 May 27;14(11):2251. doi: 10.3390/nu14112251. PMID: 35684051; PMCID: PMC9182885.

- Paterniti I, Casili G, Filippone A, Lanza M, **Ardizzone A**, Capra AP, Campolo M, Esposito E. A New Approach for the Treatment of Recurrent Vulvovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo. *J Fungi (Basel)*. 2022 Nov 27;8(12):1251. doi: 10.3390/jof8121251. PMID: 36547584; PMCID: PMC9787890.

- Scuderi SA, Casili G, Lanza M, **Ardizzone A**, Pantaleo L, Campolo M, Paterniti I, Cucinotta L, Cuzzocrea S, Esposito E. Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model. *Int J Mol Sci*. 2022 Feb 18;23(4):2269. doi: 10.3390/ijms23042269. PMID: 35216383; PMCID: PMC8875977.

- Filippone A, **Ardizzone A**, Bova V, Lanza M, Casili G, Cuzzocrea S, Esposito E, Campolo M, Paterniti I. A Combination of Xyloglucan, Pea Protein and Chia Seed Ameliorates Intestinal Barrier Integrity and Mucosa Functionality in a Rat Model of Constipation-Predominant Irritable Bowel Syndrome. *J Clin Med*. 2022 Nov 29;11(23):7073. doi: 10.3390/jcm11237073. PMID: 36498647; PMCID: PMC9739531.

- Filippone A, Casili G, Lanza M, Scuderi SA, **Ardizzone A**, Capra AP, Paterniti I, Campolo M, Cuzzocrea S, Esposito E. Evaluation of the Efficacy of Xyloglucan, Pea Protein and *Opuntia ficus-indica* Extract in a Preclinical Model of Psoriasis. *Int J Mol Sci*. 2023 Feb 4;24(4):3122. doi: 10.3390/ijms24043122. PMID: 36834534; PMCID: PMC9966091.

- **Ardizzone A**, Mannino D, Casili G, Campolo M, Paterniti I, Lanza M, Filippone A, Repici A, Bova V, Capra AP, Cuzzocrea S, Esposito E. Efficacy of an oral suspension containing xyloglucan and pea proteins on a murine model of gastroesophageal reflux disease. *Phytother Res*. 2024 Jan 31. doi: 10.1002/ptr.8133. PMID: 38296262.

2020 – to date Collaboration with the pharmaceutical company DEVINTEC in the production of the following publications:

- Lanza M, Casili G, Torre GL, Giuffrida D, Rotondo A, Esposito E, **Ardizzone A**, Rando R, Bartolomeo G, Albergamo A, Vadalà R, Salvo A. Properties of a New Food Supplement Containing *Actinia equina* Extract. *Antioxidants (Basel)*. 2020 Oct 1;9(10):945. doi: 10.3390/antiox9100945. PMID: 33019631; PMCID: PMC7600189.

2022 – to date Collaboration with Prof. Silvana Briuglia of the Genetics and Pharmacogenetics Unit of the Gaetano Martino University Hospital, resulting in the following publications:

- **Ardizzone A**, Capra AP, Campolo M, Filippone A, Esposito E, Briuglia S. Neurofibromatosis: New Clinical Challenges in the Era of COVID-19. *Biomedicines*. 2022 Apr 19;10(5):940. doi: 10.3390/biomedicines10050940. PMID: 35625677; PMCID: PMC9138859.

- Capra AP, **Ardizzone A**, Briuglia S, La Rosa MA, Mondello S, Campolo M, Esposito E. A Systematic Review and Meta-Analysis of the Association between the FV H1299R Variant and the Risk of Recurrent Pregnancy Loss. *Biology (Basel)*. 2022 Nov 3;11(11):1608. doi: 10.3390/biology11111608. PMID: 36358309; PMCID: PMC9687207.

- **Ardizzone A**, Capra AP, Mondello S, Briuglia S, La Rosa MA, Campolo M, Esposito E. H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. *Genes (Basel)*. 2022 Jun 6;13(6):1019. doi: 10.3390/genes13061019. PMID: 35741781; PMCID: PMC9222435.

2023 – to date Collaboration with Prof. Raffele Squeri of the Hospital Hygiene Unit of the Gaetano Martino University Hospital with the production of the following publications:

- Capra AP, **Ardizzone A**, Pantò G, Paterniti I, Campolo M, Crupi L, Squeri R, Esposito E. The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence. *Int J Mol Sci*. 2023 Feb 10;24(4):3537. doi: 10.3390/ijms24043537. PMID: 36834949; PMCID: PMC9958638.

- Capra AP, Crupi L, Pantò G, Repici A, Calapai F, Squeri R, **Ardizzone A***, Esposito E. Serum Pentraxin 3 as Promising Biomarker for the Long-Lasting Inflammatory Response of COVID-19. *Int J Mol Sci*. 2023 Sep 17;24(18):14195. doi: 10.3390/ijms241814195. PMID: 37762499; PMCID: PMC10531731. * corresponding author

2024 – to date Collaboration with Prof. Filippo Benedetto of the Vascular Surgery Unit at the G. Martino University Hospital, resulting in the following publications:

- Crupi L, **Ardizzone A**, Calapai F, Scuderi SA, Benedetto F, Esposito E, Capra AP. The Impact of COVID-19 on Amputation and Mortality Rates in Patients with Acute Limb Ischemia: A Systematic Review and Meta-Analysis. *Diseases*. 2024; 12(4):74. <https://doi.org/10.3390/diseases12040074>

2024 – ad oggi Collaboration with Prof. Nicola Silvestris, Director of the Medical Oncology Department at the Giovanni Paolo II Cancer Institute in Bari, a scientific hospital and research institute, resulting in the following publications:

- **Ardizzone A**, Bulzoni M, De Luca F, Silvestris N, Esposito E, Capra AP. Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients. *Current Issues in Molecular Biology*. 2024; 46(9):9831-9843. <https://doi.org/10.3390/cimb46090584>

2025 – ad oggi Collaboration with Dr. Marco Galletta, head of the Medically Assisted Procreation (MAP) center at Papardo Hospital, with the production of the following publications:

- **Ardizzone A**, Liuzzo C, Ferro A, Galletta M, Esposito E, Capra AP. PTX3/NF-κB/TLR4 Pathway Evaluation in the Follicular Fluid to Successfully Predict Blastocyst Implantation: A Pilot Study. *Biomedicines*. 2025 Apr 28;13(5):1071. doi: 10.3390/biomedicines13051071. PMID: 40426899; PMCID: PMC12109426.

PARTECIPATION IN COURSES AND SEMINAR

1. Conference on “Equivalent-biosimilar drugs: Quality, efficacy, and sustainability” – Motori Sanità, Messina, Italy (October 14, 2017) at the University of Messina.

2. ECM training course "Nutrition and sport: an essential combination" held by InPha - Nutraceuticals with a high level of scientific rigor, Messina, Italy (April 28, 2018) at the University of Messina.
3. Series of webinars entitled "Medicines: regulatory tools" (September 30, October 12, November 9, 2020) promoted by the Italian Society of Pharmacology (SIF).
4. "Quality Management System - Operational Aspects" M. Biscaro. (November 6, 2020) at the University of Messina.
5. "Quality Management System - Recording of Experiments and Management of Measuring Instruments and Related Records" M. Biscaro, on-the-job training. (9/04/2021) at the University of Messina.
6. "Pharmacognosy yesterday, today and tomorrow" SIPHAR Web Conference (18/06/2021) promoted by the Italian Society of Pharmacology (SIF).
7. UniME School of Excellence 2021: "Immunity and inflammation, from cancer to COVID-19" Speaker: Prof. Alberto Mantovani (July 26, 2021) at the University of Messina.
8. "Quality Management System - Applicable requirements of ISO 13485: 2016 and ISO 9001: 2015 standards, procedures, and registration forms" M. Biscaro (September 10, 2021) at the University of Messina.
9. Course on "Fire Safety Training" (10/25/2021) at the University of Glasgow.
10. Course on "Health, Safety, and Wellbeing" (10/25/2021) at the University of Glasgow.
11. Webinar on Cardiovascular Research Discoveries (11/3/2021) at the University of Glasgow.
12. Scientific Dissemination Seminar "Glucocorticoids in Inflammation and Immune Response: Role of GILZ" by Professor Carlo Riccardi, (June 30, 2022) at the University of Messina.
13. Overview of Suppression Methods (Messina, July 12, 2022) at the University of Messina.
14. Severity of procedures, humanitarian endpoints (Messina, July 12, 2022) at the University of Messina.
15. The three Rs in the science of animal use (Messina, July 12, 2022) at the University of Messina.
16. Alternative approaches and research methodology (Messina, July 12, 2022) at the University of Messina.
17. Education and training on the use of the Agilent 1260 Infinity II HPLC instrument. (Messina, 29/09/2022) at the University of Messina.
18. Specific training for laboratory staff on the management of laboratory instruments, equipment, and materials (Messina, 13/10/2022) at the University of Messina.
19. Satellite International Workshop "Obesity and eating disorders," June 7-8, 2024,

Camerino.

20. 3 SIF-ECPG Masterclasses “Pharmacologists 2.0” - Skills for Success: Leadership, Grant Writing, and AI at the Menarini Foundation headquarters, Fiesole (FI), March 6-8, 2025.

21. First Aid Course at the Italian Red Cross (Messina Territorial Committee), from March 10, 2025, to April 4, 2025; Medical Responder Certification issued on April 6, 2025.

22. Dissemination Day: Innovative therapeutic strategies in the treatment of glioblastoma: focus on molecular and clinical approaches, Messina, September 22, 2025..

PREMI E RICONOSCIMENTI

- 2022** Italian Society of Pharmacology (SIF) young fellowship for a period of research abroad at the University of Glasgow awarded by the Italian Society of Pharmacology.
- 2023** Best Oral Communication Award at the 1st Inter-Society Congress on Plant Products for Health: The Role of Medicinal Plants in Modern Medicine, Padua, June 15-17, 2023.
- 2023** Invited Chairperson to moderate the oral communications session “Inflammation Pharmacology and Immunopharmacology” at the XXV Conference of Young SIF Pharmacologists 2023, Urbino (PU), September 5-8, 2023.
- 2023** SIF Farindustria Award for pharmacological research issued by the Italian Society of Pharmacology and Farindustria.
- 2024** “Fondazione Celeghin” Award issued by the Italian Association of Neuro-Oncology (AINO).

MEMBERSHIP IN SCIENTIFIC SOCIETIES

- Italian Society of Pharmacology (SIF)
- British Pharmacological Society (BPS)
- Society for Neuroscience (SfN)
- Italian Society of Hospital Pharmacy (SIFO)

PUBLISHING ACTIVITIES

Reviewer for:

- Biomedicines
- Cancers
- Cell Biology International
- Clinical and Experimental Metastasis

- Diagnostics
- Genes & Diseases
- International Journal of Molecular Sciences
- Journal of Clinical Medicine
- Pharmadvances

EDITORIAL BOARD for:

- **Pharmadvances** (as Young PharmAdvisory Board).

- **Guest Editor** for the Special Issue "Immune-Inflammatory and Oxidative Stress Signaling Pathways Involved in Human Disorders" in International Journal of Molecular Sciences (IJMS).

- **Reviewer Board** Member in the "Biomedicines" journal Impact Factor 3.9 (Q1 in 'Pharmacology and Pharmacy'), Open access journal dedicated to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research in the field of biomedicine, pharmaceuticals, and biopharmaceuticals of natural origin. MDPI (from 01-10-2024 to date).

- **Guest Editor** for the Special Issue "Investigating Gut Axes: Pathophysiological Functions and Therapeutic Strategies" in International Journal of Molecular Sciences (IJMS).

- **Editor** for the Collection "Biomarkers and Therapeutic Targets for Central Nervous System Tumors" in the Discover Oncology journal (Springer Nature)

SCIENTIFIC ACTIVITY

The research carried out by Dr. Alessio Ardizzone is documented by:

- 62 publications in international journals classified according to ISI Web of Knowledge;

Scopus parameters: h-index: 20; Total citations: 908 (october 2025)

Full-length works published in international journals classified in ISI Web of Knowledge

Publications

1. Campolo M, Casili G, Paterniti I, Filippone A, Lanza M, **Ardizzone A**, Scuderi SA, Cuzzocrea S, Esposito E. Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis. *Int J Mol Sci*. 2020 May 19;21(10):3596. doi: 10.3390/ijms21103596. PMID: 32438777; PMCID: PMC7279434.

2. Filippone A, Consoli GML, Granata G, Casili G, Lanza M, **Ardizzone A**, Cuzzocrea S, Esposito E, Paterniti I. Topical Delivery of Curcumin by Choline-Calix[4]arene-Based Nanohydrogel Improves Its Therapeutic Effect on a Psoriasis Mouse Model. *Int J Mol Sci*. 2020 Jul 17;21(14):5053. doi: 10.3390/ijms21145053. PMID: 32708987; PMCID: PMC7404063.

3. Scuderi SA[#], **Ardizzone A[#]**, Paterniti I, Esposito E, Campolo M. Antioxidant and Antiinflammatory Effect of Nrf2 Inducer Dimethyl Fumarate in Neurodegenerative Diseases. *Antioxidants (Basel)*. 2020 Jul 17;9(7):630. doi: 10.3390/antiox9070630. PMID: 32708926; PMCID: PMC7402174. #co-author

4. Casili G, Campolo M, Lanza M, Filippone A, Scuderi S, Messina S, **Ardizzone A**, Esposito E, Paterniti I. Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury. *Mol Neurobiol*. 2020 Nov;57(11): 4394-4407. doi: 10.1007/s12035-020-02033-x. Epub 2020 Jul 29. PMID: 32729104.

5. Campolo M, Lanza M, Filippone A, Paterniti I, Casili G, Scuderi SA, **Ardizzone A**, Cuzzocrea S, Esposito E. Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier

Permeability. *Skin Pharmacol Physiol.* 2020;33(4):231-236. doi: 10.1159/000509372. Epub 2020 Aug 26. PMID: 32846412.

6. Lanza M, Casili G, Torre GL, Giuffrida D, Rotondo A, Esposito E, **Ardizzone A**, Rando R, Bartolomeo G, Albergamo A, Vadal. R, Salvo A. Properties of a New Food Supplement Containing *Actinia equina* Extract. *Antioxidants (Basel).* 2020 Oct 1;9(10):945. doi: 10.3390/antiox9100945. PMID: 33019631; PMCID: PMC7600189.

7. Casili G, Lanza M, Campolo M, Siracusa R, Paterniti I, **Ardizzone A**, Scuderi SA, Cuzzocrea S, Esposito E. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation. *Int J Mol Sci.* 2020 Oct 11;21(20):7486. doi: 10.3390/ijms21207486. PMID: 33050589; PMCID: PMC7589809.

8. Casili G, **Ardizzone A**, Lanza M, Gugliandolo E, Portelli M, Militi A, Cuzzocrea S, Esposito E, Paterniti I. Treatment with Luteolin Improves Lipopolysaccharide-Induced Periodontal Diseases in Rats. *Biomedicines.* 2020 Oct 21;8(10):442. doi: 10.3390/biomedicines8100442. PMID: 33096800; PMCID: PMC7590181.

9. Casili G, Lanza M, Campolo M, Messina S, Scuderi S, **Ardizzone A**, Filippone A, Paterniti I, Cuzzocrea S, Esposito E. Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency. *Vascul Pharmacol.* 2021 Apr; 137:106825. doi: 10.1016/j.vph.2020.106825. Epub 2020 Dec 2. PMID: 33278582.

10. **Ardizzone A**, Scuderi SA, Giuffrida D, Colarossi C, Puglisi C, Campolo M, Cuzzocrea S, Esposito E, Paterniti I. Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. *Cancers (Basel).* 2020 Dec 18;12(12):3825. doi: 10.3390/cancers12123825. PMID: 33352931; PMCID: PMC7766440.

11. **Ardizzone A**, Fusco R, Casili G, Lanza M, Impellizzeri D, Esposito E, Cuzzocrea S. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-L- Carnitine on Experimental Model of Inflammatory Pain. *Int J Mol Sci.* 2021 Feb 17;22(4):1967. doi: 10.3390/ijms22041967. PMID: 33671213; PMCID: PMC7922157.

12. Calabrese G[#], **Ardizzone A**[#], Campolo M, Conoci S, Esposito E, Paterniti I. Beneficial Effect of Tempol, a Membrane-Permeable Radical Scavenger, on Inflammation and Osteoarthritis in In Vitro Models. *Biomolecules.* 2021 Feb 25; 11 (3): 352. doi: 10.3390/biom11030352. PMID: 33669093; PMCID: PMC7996488. ^{#co-author}

13. Campolo M, Lanza M, Paterniti I, Filippone A, **Ardizzone A**, Casili G, Scuderi SA, Puglisi C, Mare M, Memeo L, Cuzzocrea S, Esposito E. PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-κB/Nrf-2 Axis. *Int J Mol Sci.* 2021 Apr 10; 22 (8): 3927. doi: 10.3390/ijms22083927. PMID: 33920318; PMCID: PMC8069952.

14. **Ardizzone A**, Calabrese G, Campolo M, Filippone A, Giuffrida D, Esposito F, Colarossi C, Cuzzocrea S, Esposito E, Paterniti I. Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis. *Int J Mol Sci.* 2021 Apr 29; 22 (9): 4697. doi: 10.3390/ijms22094697. PMID: 33946718; PMCID: PMC8125123.

15. Scuderi SA, Casili G, **Ardizzone A**, Forte S, Colarossi L, Sava S, Paterniti I, Esposito E, Cuzzocrea S, Campolo M. KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces Glioblastoma Proliferation through Angiogenesis and Apoptosis Modulation. *Cancers (Basel).* 2021 Jul 9; 13 (14): 3444. doi: 10.3390/cancers13143444. PMID: 34298658; PMCID: PMC8306782.

16. Campolo M, Casili G, Lanza M, Filippone A, Cordaro M, **Ardizzone A**, Scuderi SA, Cuzzocrea S, Esposito E, Paterniti I. The inhibition of mammalian target of rapamycin (mTOR) in improving inflammatory response after traumatic brain injury. *J Cell Mol Med.* 2021 Aug; 25 (16): 7855-7866. doi: 10.1111/jcmm.16702. Epub 2021 Jul 10. PMID: 34245104; PMCID: PMC8358860.

17. Campolo M, Crupi R, Cordaro M, Cardali SM, **Ardizzone A**, Casili G, Scuderi SA, Siracusa R, Esposito E, Conti A, Cuzzocrea S. Co-Ultra PEA-Lut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury. *Int J Mol Sci.* 2021 Aug 13; 22 (16): 8717. doi: 10.3390/ijms22168717. PMID: 34445417; PMCID: PMC8395716.

18. Filippone A#, Casili G#, **Ardizzone A**, Lanza M, Mannino D, Paterniti I, Esposito E, Campolo M. Inhibition of Prolyl Oligopeptidase Prevents Consequences of Reperfusion following Intestinal Ischemia. *Biomedicines*. 2021 Sep 29; 9 (10): 1354. doi: 10.3390/biomedicines9101354. PMID: 34680471; PMCID: PMC8533609. #co-author
19. Lanza M#, Filippone A#, **Ardizzone A**, Casili G, Paterniti I, Esposito E, Campolo M. SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine. *Cells*. 2021 Oct 14; 10 (10): 2756. doi: 10.3390/cells10102756. PMID: 34685736; PMCID: PMC8535085. #co-author
20. Casili G, **Ardizzone A**, Basilotta R, Lanza M, Filippone A, Paterniti I, Esposito E, Campolo M. The Protective Role of Prolyl Oligopeptidase (POP) Inhibition in Kidney Injury Induced by Renal Ischemia-Reperfusion. *Int J Mol Sci*. 2021 Nov 2;22(21):11886. doi: 10.3390/ijms22111886. PMID: 34769337; PMCID: PMC8584363.
21. Scuderi SA, Casili G, Lanza M, **Ardizzone A**, Pantaleo L, Campolo M, Paterniti I, Cucinotta L, Cuzzocrea S, Esposito E. Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model. *Int J Mol Sci*. 2022 Feb 18;23(4):2269. doi: 10.3390/ijms23042269. PMID: 35216383; PMCID: PMC8875977.
22. Campolo M., Gallo G., Roviello F., **Ardizzone A**, La T. M., Filippone A., Lanza M., Cuzzocrea S., Siroli L., and Esposito E. 2022. "Evaluation of a Gel Containing a Propionibacterium Extract in an In Vivo Model of Wound Healing" *International Journal of Molecular Sciences* 23, no. 9: 4708. doi: 10.3390/ijms23094708. PMID: 35563099; PMCID: PMC9101165.
23. **Ardizzone A**, Capra AP, Campolo M, Filippone A, Esposito E, Briuglia S. Neurofibromatosis: New Clinical Challenges in the Era of COVID-19. *Biomedicines*. 2022 Apr 19;10(5):940. doi: 10.3390/biomedicines10050940. PMID: 35625677; PMCID: PMC9138859.
24. **Ardizzone A**, Bova V, Casili G, Filippone A, Campolo M, Lanza M, Esposito E, Paterniti I. SUN11602, a bFGF mimetic, modulated neuroinflammation, apoptosis and calcium-binding proteins in an in vivo model of MPTP-induced nigrostriatal degeneration. *J Neuroinflammation*. 2022 May 7;19(1):107. doi: 10.1186/s12974-022-02457-3. PMID: 35526035; PMCID: PMC9080217.
25. **Ardizzone A**, Lanza M, Casili G, Campolo M, Paterniti I, Cuzzocrea S, Esposito E. Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion. *Nutrients*. 2022 May 27;14(11):2251. doi: 10.3390/nu14112251. PMID: 35684051; PMCID: PMC9182885.
26. **Ardizzone A**, Capra AP, Mondello S, Briuglia S, La Rosa MA, Campolo M, Esposito E. H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. *Genes (Basel)*. 2022 Jun 6;13(6):1019. doi: 10.3390/genes13061019. PMID: 35741781; PMCID: PMC9222435.
27. **Ardizzone A**, Filippone A, Mannino D, Scuderi SA, Casili G, Lanza M, Cucinotta L, Campolo M, Esposito E. Ulva pertusa, a Marine Green Alga, Attenuates DNBS-Induced Colitis Damage via NF- κ B/Nrf2/SIRT1 Signaling Pathways. *J Clin Med*. 2022 Jul 25;11(15):4301. doi: 10.3390/jcm11154301. PMID: 35893393; PMCID: PMC9331369.
28. Capra AP#, **Ardizzone A**#, Briuglia S, La Rosa MA, Mondello S, Campolo M, Esposito E. A Systematic Review and Meta-Analysis of the Association between the FV H1299R Variant and the Risk of Recurrent Pregnancy Loss. *Biology (Basel)*. 2022 Nov 3;11(11):1608. doi: 10.3390/biology11111608. PMID: 36358309. #co-author
29. Paterniti I, Casili G, Filippone A, Lanza M, **Ardizzone A**, Capra AP, Campolo M, Esposito E. A New Approach for the Treatment of Recurrent Vulvovaginal Candidiasis with a Combination of Pea Protein, Grape Seed Extract, and Lactic Acid Assessed In Vivo. *J Fungi (Basel)*. 2022 Nov 27;8(12):1251. doi: 10.3390/jof8121251. PMID: 36547584; PMCID: PMC9787890.
30. Filippone A, **Ardizzone A**, Bova V, Lanza M, Casili G, Cuzzocrea S, Esposito E, Campolo M,

Paterniti I. A Combination of Xyloglucan, Pea Protein and Chia Seed Ameliorates Intestinal Barrier Integrity and Mucosa Functionality in a Rat Model of Constipation-Predominant Irritable Bowel Syndrome. *J Clin Med*. 2022 Nov 29;11(23):7073. doi: 10.3390/jcm11237073. PMID: 36498647; PMCID: PMC9739531.

31. Filippone A, Casili G, Lanza M, Scuderi SA, **Ardizzone A**, Capra AP, Paterniti I, Campolo M, Cuzzocrea S, Esposito E. Evaluation of the Efficacy of Xyloglucan, Pea Protein and *Opuntia ficus indica* Extract in a Preclinical Model of Psoriasis. *Int J Mol Sci*. 2023 Feb 4;24(4):3122. doi: 10.3390/ijms24043122. PMID: 36834534; PMCID: PMC9966091.

32. Capra AP#, **Ardizzone A**#, Pantò G, Paterniti I, Campolo M, Crupi L, Squeri R, Esposito E. The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence. *Int J Mol Sci*. 2023 Feb 10;24(4):3537. doi: 10.3390/ijms24043537. PMID: 36834949; PMCID: PMC9958638. #co-author

33. **Ardizzone A**, Basilotta R, Filippone A, Crupi L, Lanza M, Lombardo SP, Colarossi C, Sciacca D, Cuzzocrea S, Esposito E, Campolo M. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. *Cells*. 2023 Mar 8;12(6):841. doi: 10.3390/cells12060841. PMID: 36980182; PMCID: PMC10046911.

34. **Ardizzone A**, Bova V, Casili G, Repici A, Lanza M, Giuffrida R, Colarossi C, Mare M, Cuzzocrea S, Esposito E, Paterniti I. Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value. *Cells*. 2023 Mar 24;12(7):1002. doi: 10.3390/cells12071002. PMID: 37048074; PMCID: PMC10093572.

35. **Ardizzone A**, Mannino D, Capra AP, Repici A, Filippone A, Esposito E, Campolo M. New Insights into the Mechanism of *Ulva pertusa* on Colitis in Mice: Modulation of the Pain and Immune System. *Mar Drugs*. 2023 May 13;21(5):298. doi: 10.3390/md21050298. PMID: 37233492; PMCID: PMC10223675.

36. **Ardizzone A**, Repici A, Capra AP, De Gaetano F, Bova V, Casili G, Campolo M, Esposito E. Efficacy of the Radical Scavenger, Tempol, to Reduce Inflammation and Oxidative Stress in a Murine Model of Atopic Dermatitis. *Antioxidants (Basel)*. 2023 Jun 15;12(6):1278. doi: 10.3390/antiox12061278. PMID: 37372008; PMCID: PMC10294991.

37. Capra AP, **Ardizzone A**, Crupi L, Calapai F, Campolo M, Cuzzocrea S, Esposito E. Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies. *Biomedicines*. 2023 Aug 3;11(8):2189. doi: 10.3390/biomedicines11082189. PMID: 37626685; PMCID: PMC10452638.

38. Repici A, **Ardizzone A**, Filippone A, Colarossi C, Mare M, Raciti G, Mannino D, Cuzzocrea S, Paterniti I, Esposito E. Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential. *Cells*. 2023 Sep 15;12(18):2284. doi: 10.3390/cells12182284. PMID: 37759505; PMCID: PMC10526836.

39. Capra AP, Crupi L, Pantò G, Repici A, Calapai F, Squeri R, **Ardizzone A***, Esposito E. Serum Pentraxin 3 as Promising Biomarker for the Long-Lasting Inflammatory Response of COVID-19. *Int J Mol Sci*. 2023 Sep 17;24(18):14195. doi: 10.3390/ijms241814195. PMID: 37762499; PMCID: PMC10531731.*corresponding author

40. **Ardizzone A**, Bova V, Casili G, Filippone A, Lanza M, Repici A, Esposito E, Paterniti I. bFGF-like Activity Supported Tissue Regeneration, Modulated Neuroinflammation, and Rebalanced Ca²⁺ Homeostasis following Spinal Cord Injury. *Int J Mol Sci*. 2023 Sep 27;24(19):14654. doi: 10.3390/ijms241914654. PMID: 37834102; PMCID: PMC10572408.

41. **Ardizzone A**, Capra AP, Repici A, Lanza M, Bova V, Palermo N, Paterniti I, Esposito E. Rebalancing NOX2/Nrf2 to limit inflammation and oxidative stress across gut-brain axis in migraine. *Free Radic Biol Med*. 2024 Jan 19;213:65-78. doi: 10.1016/j.freeradbiomed.2024.01.018. PMID: 38244728.

42. Crupi L, Capra AP, Paterniti I, Lanza M, Calapai F, Cuzzocrea S, **Ardizzone A***, Esposito E. Evaluation of the nutraceutical Palmitoylethanolamide in reducing intraocular pressure (IOP) in

patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. *Nat Prod Res.* 2024 Jan 25;1-20. doi: 10.1080/14786419.2024.2306916. Epub ahead of print. PMID: 38269580. *corresponding author

43. **Ardizzone A**, Mannino D, Casili G, Campolo M, Paterniti I, Lanza M, Filippone A, Repici A, Bova V, Capra AP, Cuzzocrea S, Esposito E. Efficacy of an oral suspension containing xyloglucan and pea proteins on a murine model of gastroesophageal reflux disease. *Phytother Res.* 2024 Jan 31. doi: 10.1002/ptr.8133. PMID: 38296262.

44. Repici A, **Ardizzone A**, De Luca F, Colarossi L, Prestifilippo A, Pizzino G, Paterniti I, Esposito E, Capra AP. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma. *Cells.* 2024 Feb 19;13(4):361. doi: 10.3390/cells13040361. PMID: 38391974; PMCID: PMC10886920.

45. Crupi L, **Ardizzone A**, Calapai F, Scuderi SA, Benedetto F, Esposito E, Capra AP. The Impact of COVID-19 on Amputation and Mortality Rates in Patients with Acute Limb Ischemia: A Systematic Review and Meta-Analysis. *Diseases.* 2024 Apr 7;12(4):74. doi: 10.3390/diseases12040074. PMID: 38667532; PMCID: PMC11048752.

46. Repici A, Capra AP, Hasan A, Bulzom. M, Campolo M, Paterniti I, Esposito E, **Ardizzone A**. Novel Findings on CCR1 Receptor in CNS Disorders: A Pathogenic Marker Useful in Controlling Neuroimmune and Neuroinflammatory Mechanisms in Parkinson's Disease. *Int J Mol Sci.* 2024 Apr 14;25(8):4337. doi: 10.3390/ijms25084337. PMID: 38673922; PMCID: PMC11050472.

47. Scuderi SA, **Ardizzone A**, Salako AE, Pant. G, De Luca F, Esposito E, Capra AP. Pentraxin 3: A Main Driver of Inflammation and Immune System Dysfunction in the Tumor Microenvironment of Glioblastoma. *Cancers (Basel).* 2024 Apr 24;16(9):1637. doi: 10.3390/cancers16091637. PMID: 38730589; PMCID: PMC11083335.

48. Repici A, Hasan A, Capra AP, Scuderi SA, Paterniti I, Campolo M, **Ardizzone A***, Esposito E. Marine Algae and Deriving Biomolecules for the Management of Inflammatory Bowel Diseases: Potential Clinical Therapeutics to Decrease Gut Inflammatory and Oxidative Stress Markers? *Mar Drugs.* 2024 Jul 25;22(8):336. doi: 10.3390/md22080336. PMID: 39195452; PMCID: PMC11355360. *corresponding author

49. **Ardizzone A**, Scuderi SA, Crupi L, Campolo M, Paterniti I, Capra AP, Esposito E. Linking GERD and the Peptide Bombesin: A New Therapeutic Strategy to Modulate Inflammatory, Oxidative Stress and Clinical Biochemistry Parameters. *Antioxidants (Basel).* 2024 Aug 28;13(9):1043. doi: 10.3390/antiox13091043. PMID: 39334702; PMCID: PMC11428475.

50. **Ardizzone A**, Bulzom. M, De Luca F, Silvestris N, Esposito E, Capra AP. Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients. *Curr Issues Mol Biol.* 2024 Sep 4;46(9):9831-9843. doi: 10.3390/cimb46090584. PMID: 39329936; PMCID: PMC11430620.

51. Hasan A, Repici A, Capra AP, Mannino D, Bova V, Catalfamo A, Campolo M, Paterniti I, Esposito E, **Ardizzone A**. CCR1 antagonist as a potential modulator of inflammatory, autophagic, and apoptotic markers in spinal cord injury. *Neuropharmacology.* 2024 Nov 26;264:110239. doi: 10.1016/j.neuropharm.2024.110239. Epub ahead of print. PMID: 39608704.

52. Repici A, Capra AP, Hasan A, Basilotta R, Scuderi SA, Campolo M, Paterniti I, Esposito E, **Ardizzone A**. Ulva pertusa Modulated Colonic Oxidative Stress Markers and Clinical Parameters: A Potential Adjuvant Therapy to Manage Side Effects During 5-FU Regimen. *Int J Mol Sci.* 2024 Dec 3;25(23):12988. doi: 10.3390/ijms252312988. PMID: 39684698; PMCID: PMC11641785.

53. Hasan A[#], **Ardizzone A[#]**, Giosa D, Scuderi SA, Calcaterra E, Esposito E, Capra AP. The Therapeutic Potential of MicroRNA-21 in the Treatment of Spinal Cord Injury. *Curr Issues Mol Biol.* 2025 Jan 21;47(2):70. doi: 10.3390/cimb47020070. PMID: 39996791; PMCID: PMC11854632. #coauthors

54. **Ardizzone A**, Siracusa R, Capra AP, Di Paola R, Esposito E, Cuzzocrea S, D'Amico R, Impellizzeri D. Evaluating osteopontin as a biomarker of obesity related complications before and after metabolic and bariatric surgery: A systematic review and meta-analysis. *Obes Res Clin Pract*. 2025 Jan-Feb;19(1):19-27. doi: 10.1016/j.orcp.2025.01.010. Epub 2025 Jan 30. PMID: 39884900.
55. Scuderi SA, **Ardizzone A**, Esposito E, Capra AP. ABCB1-Mediated Colchicine Transport and Its Implications in Familial Mediterranean Fever: A Systematic Review. *Curr Issues Mol Biol*. 2025 Mar 20;47(3):210. doi: 10.3390/cimb47030210. PMID: 40136464; PMCID: PMC11941201.
56. Cucinotta L#, Palermo N#, **Ardizzone A**, Capra AP, Campolo M, Esposito E, Casili G, Lanza M. The Inhibition of Prolyl Endopeptidase (PREP) by KYP-2047 Treatment to Reduce Myocardial Ischemia/Reperfusion Injury. *Antioxidants (Basel)*. 2025 Apr 8;14(4):442. doi: 10.3390/antiox14040442. PMID: 40298805. #co-author
57. **Ardizzone A**, Liuzzo C, Ferro A, Galletta M, Esposito E, Capra AP. PTX3/NF- κ B/TLR4 Pathway Evaluation in the Follicular Fluid to Successfully Predict Blastocyst Implantation: A Pilot Study. *Biomedicines*. 2025 Apr 28;13(5):1071. doi: 10.3390/biomedicines13051071. PMID: 40426899; PMCID: PMC12109426.
58. **Ardizzone A**, Scuderi SA, Casili G, Basilotta R, Esposito E, Lanza M. PI3K/mTOR Signaling Pathway Dual Inhibition for the Management of Neuroinflammation: Novel Insights from In Vitro Models. *Biomolecules*. 2025 May 7;15(5):677. doi: 10.3390/biom15050677. PMID: 40427570; PMCID: PMC12108750.
59. Hasan A, Scuderi SA, Capra AP, Giosa D, Bonomo A, **Ardizzone A***, Esposito E. An Updated and Comprehensive Review Exploring the Gut–Brain Axis in Neurodegenerative Disorders and Neurotraumas: Implications for Therapeutic Strategies. *Brain Sciences*. 2025; 15(6):654. <https://doi.org/10.3390/brainsci15060654> *corresponding author
60. **Ardizzone A**, Cucinotta L, Casili G, Lanza M, Hasan A, Campolo M, Esposito E, Paterniti I. GIT 27 Modulates TLR4/Src/NOX2 Signaling Pathway: A Potential Therapeutic Strategy to decrease Neuroinflammation, Oxidative Stress and Neuronal Cell Death in Parkinson's Disease. *Free Radic Biol Med*. 2025 Jun 20:S0891-5849(25)00784-1. doi: 10.1016/j.freeradbiomed.2025.06.035. Epub ahead of print. PMID: 40545151.
61. Filippone A, Casili G, Lanza M, Campolo M, Paterniti I, Cucinotta L, Basilotta R, **Ardizzone A**, Esposito E. A Topical Combination of Xyloglucan and Pea Protein Effectively Manages Oral Ulcers In Vivo. *J Oral Pathol Med*. 2025 Aug 11. doi: 10.1111/jop.70029. Epub ahead of print. PMID: 40790533.
62. Scuderi SA#, **Ardizzone A#**, Calcaterra E, Palermo N, De Luca F, Catalfamo A, Esposito E, Capra AP. The Gut–Brain Axis in Brain Tumors: Insights into Tumor Development, Progression, and Therapy. *Biomedicines*. 2025; 13(9):2172. <https://doi.org/10.3390/biomedicines13092172> #coauthors

PARTICIPATION IN CONFERENCES

Conferences

1. 2nd Congress on Nutraceuticals, Nutrition and Health at the University of Messina, Messina (Italy). Focus: Treatment of pain with nutraceutical products. Scientific Responsible: Prof. Gioacchino Calapai (04/10/2019–05/10/2019).
2. 39th National Congress of the Italian Society of Pharmacology, "RESEARCH, INNOVATION, SUSTAINABILITY, APPROPRIATENESS, TRAINING" (Florence, November 20-23, 2019).
3. SINS PhD Meeting Webinar: **Oral Communication**: "TLR7/8 deletion reduce the pathogenesis of Parkinson's Disease" (29-30 September 2020).

4. 40th SIF National Congress **Poster**: "Treatment with Luteolin improves Lipopolysaccharide-Induced Periodontitis in Rats" (Online Congress, 9-13 March 2021).
5. 1st Meeting of the SIF Immunopharmacology Working Group, "Recent Developments in Immunopharmacology"; **Poster**: Beneficial effects of *Ulva pertusa* in an experimental model of inflammatory bowel disease (Perugia, November 24-26, 2021).
6. 15th World Congress on Inflammation WCI 2022. **Poster**: "Ulva Pertusa extract modulates inflammation and improves antioxidant response in experimental murine colitis" (Rome, 5-8/06/2022).
7. Science Outreach Day (13 June 2022) of the PhD Course in "Applied Biology and Experimental Medicine", Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina; **Oral Communication**: "Revisioni sistematiche e meta-analisi: teoria ed applicazioni cliniche".
8. XXV SIGU National Congress; **Poster**: "The H1299R variant in factor V and recurrent miscarriage: a systematic review and meta-analysis" (Trieste, September 7-9, 2022).
9. XXIV SIF Seminar on Pharmacology for PhD Students, Fellows, Post Doc and Specialist Trainees and 41th SIF National Congress, **Oral Communication**: "Ulva Pertusa, a marine green alga, attenuates DNBS-induced colitis damage via NF- κ B/Nrf2/SIRT1 signaling pathways" (Rome, 15-19 November 2022).
10. More than Neurons III Edition, Turin 15-17 December 2022 – Changing the paradigm for novel therapeutic avenues; **Poster**: "SUN11602, a bFGF mimetic, improves neurons survival and attenuates neuroinflammation in an in vivo model of traumatic brain injury".
11. 1st Inter-Society Congress on Plant Products for Health: The Role of Medicinal Plants in Modern Medicine, Padua, June 15-17, 2023, **Oral Communication**: "Effects of an oral solution containing xyloglucan and pea proteins on a murine model of gastroesophageal reflux disease".
12. XXV Conference of Young SIF Pharmacologists 2023, Urbino (PU), September 5th-8th, 2023, **Oral Communication**: "Effects of an oral solution containing xyloglucan and pea proteins on a murine model of gastroesophageal reflux disease".
13. Single-topic conference GdL SIF Infiammazione, "FROM PHAGOCYTOSIS DISCOVERY TO TODAY: NEW INSIGHTS ON INFLAMMATION", Messina 21-22 September 2023, **Oral Communication**: "New Insights into the Mechanism of *Ulva pertusa* on Colitis in Mice: Modulation of the Pain and Immune System".
14. Invited Speaker, Single-topic conference SIF - Behavioral and metabolic aspects of obesity and eating disorders, 6 – 7 June 2024, Camerino. **Oral Communication**: Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion
15. Single-topic conference SIF - Behavioral and metabolic aspects of obesity and eating disorders, 6 - 7 June 2024, Camerino. **Poster Communication**: "Bombesin modulated inflammatory and oxidative stress markers related to gastroesophageal reflux disease".
16. 56th National Congress "The clinical role of Laboratory Medicine in healthcare in the third millennium," SiBioC, Laboratory Medicine, October 8-10, 2024, Bologna. **Poster Communication**: "Pentraxin-3 as a promising biomarker in different inflammatory conditions."
17. XLV National Congress of the Italian Society of Hospital Pharmacy, October 17-20, Naples. **Poster Communication**: Screening for DPYD*6 polymorphism to reduce the risk of gastrointestinal and hematological adverse reactions in patients treated with fluoropyrimidines.
18. 42th SIF National Congress, **Poster Communications**: "DPYD*6 polymorphism screening is a useful tool for decreasing gastrointestinal and hematological adverse drug reactions risk in fluoropyrimidines-treated patients"; "The Impact of COVID-19 on Amputation and Mortality Rates in

Patients with Acute Limb Ischemia: A Systematic Review and Meta-Analysis"; EZH2 inhibitor decreases tumor growth through inflammatory and angiogenesis pathways modulation in oral squamous cell carcinoma (Sorrento, 15-19 November 2024).

19. 27th National Congress and Residential Course AINO 2024, Oral presentation: Prolyl oligopeptidase (PREP) as a tumor biomarker in patients with glioblastoma: a pilot study (Florence, December 5-7, 2024)

20. Invited speaker, Congress "The thousand faces of pharmacology: from zebrafish to humans." Messina, December 16, 2024. Oral presentation: Administration of *Ulva pertusa* as a new therapeutic strategy in the treatment of colitis.

22. 2nd Inter-Society Congress on Plant Products for Health: The role of medicinal plants in modern medicine, Naples, April 10-12, 2025, Oral presentation: "*Ulva pertusa*: markers of colon oxidative stress and modulated clinical parameters: a potential adjuvant therapy for managing side effects during 5-FU treatment."

24. 33rd National Congress of Phytotherapy, Arezzo, 16-18 May 2025. **Oral Communication:** "*Ulva pertusa* Modulated Colonic Oxidative Stress Markers and Clinical Parameters: A Potential Adjuvant Therapy to Manage Side Effects During 5-FU Regimen".

25. Single-topic conference SIF" The impact of micro- and macro-environments on immunity and inflammation: paving the way for novel immunotherapies (Perugia, 16-17 June 2025). **Oral Communication:** "Pentraxin-3 as Inflammatory Biomarker of Metabolic Alterations in Rheumatoid Arthritis: Focus on Colonic Environment And Gut-Axes"

26. Selected and invited oral presentation "*Ulva pertusa* extract as a potential adjuvant therapy for managing the side effects of 5-fluorouracil" at the 3rd marine pharmacology conference "A sea of opportunities" at the Department of Pharmacy, University of Pisa (Pisa, July 11, 2025)

27. Invited oral presentation "Aesculus hippocastanum extract exerts neuroprotective effects in an MPP+-induced Parkinson's disease model through PPAR γ activation" at the conference "Plants and Health 2025 - Phytotherapy and nutraceuticals for inflammation control: evidence and clinical perspectives" at the Department of Pharmacy of the University of Padua (Padua, September 19, 2025)

28. Oral Communication "Beneficial effects of PEA-OXA on motor and non-motor symptoms through the modulation of apoptosis in a mouse model of Parkinson's disease" at the SIF Single-Topic Conference on the Medical Use of Cannabis and Pharmacology of the Endocannabinoid System at the Aula Magna of the Rectorate of the University of Messina (Messina, October 10-11, 2025)

29. Poster Presentation "Innovative strategies for the treatment of brain tumors: targeted delivery of temozolomide using liposomes functionalized with gold nanoparticles" at the Congress of the Italian Association of Neuro-Oncology (AINO), Naples, October 23-25, 2025.